Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1996;27:1108-1114

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jyothirmayi, G. N.
Right arrow Articles by Reddi, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jyothirmayi, G. N.
Right arrow Articles by Reddi, A. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DOXAZOSIN MESYLATE

(Hypertension. 1996;27:1108-1114.)
© 1996 American Heart Association, Inc.


Articles

Doxazosin Prevents Proteinuria and Glomerular Loss of Heparan Sulfate in Diabetic Rats

Garikiparthy N. Jyothirmayi; Indira Alluru; Alluru S. Reddi

From the Department of Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark.

Abstract We examined whether blood pressure reduction or good glycemic control equally lower albuminuria by preventing glomerular loss of heparan sulfate and progression of glomerulosclerosis in streptozotocin-induced diabetic rats. We used doxazosin, an {alpha}1-adrenergic blocker, to lower systemic blood pressure, and good glycemic control was achieved by insulin treatment. Rats were killed after 20 weeks of treatment. Doxazosin significantly lowered systolic pressure in diabetic rats; however, it had no effect in normal rats. Good glycemic control also lowered systolic pressure. In diabetic rats with good glycemic control, doxazosin had an additive effect on blood pressure. Glomerular heparan sulfate synthesis was significantly lower and urinary albumin excretion higher in diabetic than in normal rats. Both doxazosin treatment and good glycemic control normalized these abnormalities in diabetic rats. Insulin normalized plasma glucose and glycosylated HbA1 concentrations in diabetic rats, as did doxazosin. Significant increases in mesangial area and glomerulosclerosis were observed in diabetic rats. Only good glycemic control normalized these pathological changes in all diabetic rats. Two-way factorial ANOVA showed an interaction between the effects of doxazosin and insulin on systolic pressure and plasma glucose. The data show that after 20 weeks of doxazosin treatment, albuminuria was reduced by 80%; however, this treatment had no significant effect on mesangial expansion or progression to glomerulosclerosis. Conversely, good glycemic control prevented all three of the preceding sequelae.


Key Words: diabetic nephropathy • blood pressure • adrenergic alpha-antagonists • antihypertensive therapy • albuminuria • rats




This article has been cited by other articles:


Home page
HypertensionHome page
J. A. Joles and H. A. Koomans
Causes and Consequences of Increased Sympathetic Activity in Renal Disease
Hypertension, April 1, 2004; 43(4): 699 - 706.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. A. Koomans, P. J. Blankestijn, and J. A. Joles
Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call
J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537.
[Abstract] [Full Text] [PDF]